olaparib

FDA approves first drug for breast cancer with BRCA geneFDA approved the first drug to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation.
Lynparza approved to treat advanced ovarian cancerFDA has approved olaparib (Lynparza, AstraZeneca) for the treatment of women with advanced ovarian cancer associated with defective BRCA genes, as determined by an FDA-approved test.
Agent active in PCa patients with BRCA mutationsIn what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.